ID   M311 [Human melanoma]
AC   CVCL_B4KR
DR   cancercelllines; CVCL_B4KR
DR   Wikidata; Q110433010
RX   PubMed=25645078;
RX   PubMed=27533468;
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Homozygous (PubMed=25645078; PubMed=27533468).
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 16-12-21; Last updated: 19-12-24; Version: 5
//
RX   PubMed=25645078; DOI=10.1186/s12943-015-0293-5; PMCID=PMC4320814;
RA   Atefi M., Titz B., Avramis E., Ng C., Wong D.J.L., Lassen A.,
RA   Cerniglia M., Escuin-Ordinas H., Foulad D., Comin-Anduix B.,
RA   Graeber T.G., Ribas A.;
RT   "Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.";
RL   Mol. Cancer 14:27.1-27.12(2015).
//
RX   PubMed=27533468; DOI=10.1080/15384101.2016.1208862; PMCID=PMC5026796;
RA   Malka-Mahieu H., Girault I., Rubington M., Leriche M., Welsch C.,
RA   Kamsu-Kom N., Zhao Q., Desaubry L., Vagner S., Robert C.;
RT   "Synergistic effects of eIF4A and MEK inhibitors on proliferation of
RT   NRAS-mutant melanoma cell lines.";
RL   Cell Cycle 15:2405-2409(2016).
//